We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes
Read MoreHide Full Article
On Jul 8, we issued an updated research report on Bio-Rad Laboratories, Inc. (BIO - Free Report) . The company’s solid prospects in the blood-typing market make us optimistic while its shrinking gross margin is a concern. The stock currently carries a Zacks Rank #3 (Hold).
This California-based manufacturer and global supplier of clinical diagnostics and life-science research products has been outperforming its industry for the past six months. The stock has gained 20.5% against the industry’s 9.6% fall.
In the first quarter of 2020, Bio-Rad witnessed solid revenue growth at both operating segments. Further, strength in many of its key product lines across major geographic regions buoyed optimism.
The uptick in core PCR and Droplet Digital PCR product revenues resulted from robust demand due to coronavirus testing and related research. Further, the FDA’s emergency use authorization (EUA) for the Droplet Digital PCR COVID-19 test kit was encouraging.
Partnerships and collaborations at the time of the pandemic seem strategic for the company. It announced in March that it is providing Real-Time qPCR products to testing laboratories worldwide to screen COVID-19 patients.
Expansion of the company’s adjusted operating margin instills optimism. A strong solvency with slight leverage, solid prospects in blood typing market and focus on international markets are other positives.
On the flip side, escalating costs and expenses are putting pressure on the bottom line. Also, foreign-exchange woes and operation in a highly competitive market raise concern.
Global macroeconomic woes stemming from the coronavirus pandemic is another headwind for the company.
Key Picks
Some better-ranked stocks from the broader medical space are Quest Diagnostics Incorporated (DGX - Free Report) , Abbott Laboratories (ABT - Free Report) and QIAGEN N.V. (QGEN - Free Report) .
QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.
Abbott’s long-term earnings growth rate is estimated at 8.6%. The company presently carries a Zacks Rank #2 (Buy).
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes
On Jul 8, we issued an updated research report on Bio-Rad Laboratories, Inc. (BIO - Free Report) . The company’s solid prospects in the blood-typing market make us optimistic while its shrinking gross margin is a concern. The stock currently carries a Zacks Rank #3 (Hold).
This California-based manufacturer and global supplier of clinical diagnostics and life-science research products has been outperforming its industry for the past six months. The stock has gained 20.5% against the industry’s 9.6% fall.
In the first quarter of 2020, Bio-Rad witnessed solid revenue growth at both operating segments. Further, strength in many of its key product lines across major geographic regions buoyed optimism.
BioRad Laboratories, Inc. Price
BioRad Laboratories, Inc. price | BioRad Laboratories, Inc. Quote
The uptick in core PCR and Droplet Digital PCR product revenues resulted from robust demand due to coronavirus testing and related research. Further, the FDA’s emergency use authorization (EUA) for the Droplet Digital PCR COVID-19 test kit was encouraging.
Partnerships and collaborations at the time of the pandemic seem strategic for the company. It announced in March that it is providing Real-Time qPCR products to testing laboratories worldwide to screen COVID-19 patients.
Expansion of the company’s adjusted operating margin instills optimism. A strong solvency with slight leverage, solid prospects in blood typing market and focus on international markets are other positives.
On the flip side, escalating costs and expenses are putting pressure on the bottom line. Also, foreign-exchange woes and operation in a highly competitive market raise concern.
Global macroeconomic woes stemming from the coronavirus pandemic is another headwind for the company.
Key Picks
Some better-ranked stocks from the broader medical space are Quest Diagnostics Incorporated (DGX - Free Report) , Abbott Laboratories (ABT - Free Report) and QIAGEN N.V. (QGEN - Free Report) .
Quest Diagnostics’ long-term earnings growth rate is projected at 7.6%. It currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.
Abbott’s long-term earnings growth rate is estimated at 8.6%. The company presently carries a Zacks Rank #2 (Buy).
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>